BIU-87 Xenograft Model Service for Bladder Cancer

The BIU-87 xenograft model is a well-established preclinical platform for evaluating novel therapeutics against bladder transitional cell carcinoma. At Alfa Cytology, we provide comprehensive, GLP-compliant BIU-87 xenograft model services---from tumor inoculation and monitoring to endpoint analysis---enabling pharmaceutical and biotech clients to accelerate their oncology drug development pipelines with robust, reproducible data.

Overview of BIU-87 Xenograft Model for Bladder Cancer

The BIU-87 cell line was originally established in 1989 from a human papillary transitional cell carcinoma (TCC) of the bladder. It exhibits epithelioid adherent morphology and retains key histological features of the primary tumor, including grade II--III TCC characteristics. The cell line demonstrates a population doubling time of approximately 34--36 hours and can form colonies in soft agar with a cloning efficiency of 23%, indicating its robust tumorigenic potential. Notably, BIU-87 cells show agglutination reactions to ConA, WGA, and PSL lectins, and express PSCA (Prostate Stem Cell Antigen), which is overexpressed in bladder cancer and serves as a valuable prognostic marker. These molecular and phenotypic traits make BIU-87 a representative model for studying superficial bladder cancer progression and therapeutic response.

In vivo, BIU-87 xenografts can be established via both subcutaneous and orthotopic routes. Subcutaneous inoculation of 5x10^7 cells in 0.2 mL medium into nude mice yields progressive tumor growth with histopathology resembling the original carcinoma. Orthotopic instillation into acid-conditioned bladders achieves a 92.9% tumor take rate (52/56 mice) within 7--36 days, with 95.2% developing superficial TCC at 12--13 days post-inoculation. MRI imaging correlates well with histological invasion extent, enabling non-invasive longitudinal monitoring. The model supports evaluation of intravesical therapies, immunotoxins, and combination regimens, and has been validated in studies assessing drug efficacy against bladder cancer xenografts.

Figure 1. Differential expression and circular characterization of circCA12 in bladder cancer. (Jiang, L, et al., 2021)

Cell Line Information: BIU-87

The following table summarizes the essential characteristics of the BIU-87 cell line relevant to xenograft model development and preclinical application:

Our Services

Alfa Cytology leverages decades of collective expertise in oncology model development to deliver the BIU-87 xenograft platform with rigorous quality control, real-time tumor monitoring, and customizable study designs. Whether your program requires standard subcutaneous efficacy studies or complex orthotopic intravesical therapy evaluation, our team ensures reproducible tumor establishment, comprehensive histopathological endpoints, and pharmacokinetic-pharmacodynamic integration to advance your bladder cancer therapeutic candidates from preclinical validation toward IND-enabling decisions.

Workflow of BIU-87 Xenograft Model Construction

Alfa Cytology follows a standardized, quality-controlled workflow to establish BIU-87 xenograft models with high reproducibility and translational relevance. The process spans cell line qualification, animal preparation, tumor inoculation, longitudinal monitoring, and terminal analysis, ensuring data integrity at every stage.

1. Cell Line Expansion & Quality Control --- BIU-87 cells are expanded from authenticated master stocks under GMP-aligned culture conditions. Cells are tested for mycoplasma contamination, viability (>95%), and passage consistency (typically within P5--P15) prior to inoculation.
2. Animal Model Selection & Acclimation --- Immunodeficient nude mice (BALB/c nu/nu or equivalent) aged 6--8 weeks are housed in SPF-grade barrier facilities. A 7-day acclimation period precedes any procedure, with baseline body weight and health status recorded.
3. Tumor Cell Preparation --- Logarithmic-phase BIU-87 cells are harvested, washed in sterile PBS, and resuspended at 2x10^7--5x10^7 cells/mL in serum-free medium or Matrigel/medium mix (1:1) for enhanced engraftment. Cell viability is confirmed by trypan blue exclusion.
4. Inoculation -- Subcutaneous Route --- A 0.2 mL cell suspension is injected subcutaneously into the right flank or armpit under aseptic conditions. Tumor growth is monitored by digital caliper measurement every 3--4 days, with volumes calculated via the modified ellipsoid formula (LxW^2/2).
5. Inoculation -- Orthotopic Route (Optional) --- For intravesical models, mouse bladders are preconditioned via mild acid washing (e.g., 0.1 M HCl for 15--20 seconds) followed by PBS neutralization. A cell suspension is instilled intravesically and retained for 1--2 hours under anesthesia. Tumor establishment is monitored by weekly MRI, with histological staging at defined intervals.
6. Treatment Initiation & Dosing --- Once tumors reach 100--200 mm^3 (subcutaneous) or are confirmed by MRI (orthotopic), animals are randomized into treatment and vehicle-control groups. Test articles are administered according to the study protocol (IP, IV, intravesical, or oral gavage) with dosing synchronized across cohorts.
7. Longitudinal Monitoring & Welfare Assessment --- Throughout the study, tumor dimensions, body weight, and clinical signs are recorded at regular intervals. Orthotopic studies utilize non-invasive MRI to track tumor invasion depth and correlate imaging findings with histopathology at necropsy.
8. Endpoint Analysis & Data Package --- At study termination, tumors are excised, weighed, and processed for histopathology (H&E, IHC for Ki67/CD34), apoptosis analysis (TUNEL), and molecular profiling. A comprehensive data package---including tumor growth curves, tumor growth inhibition (TGI%), pharmacokinetic summaries, and raw data files---is delivered to the client.

Figure 2. BIU-87 xenograft model construction workflow.

Case Study-BIU-87 Xenograft Model Development

In a representative engagement, Alfa Cytology established subcutaneous BIU-87 xenografts in immunodeficient mice to evaluate the efficacy of a novel combination therapeutic regimen. Tumors were successfully engrafted with consistent latency and growth kinetics, enabling robust statistical comparison between treatment and control cohorts. Longitudinal monitoring demonstrated dose-dependent tumor growth inhibition, with endpoint histopathology confirming reduced Ki67 proliferation index and diminished CD34-positive microvascular density in treated groups. Pharmacokinetic analysis revealed favorable exposure-response relationships. Detailed tumor growth curves, individual animal data, and biomarker quantification are available upon request under confidentiality agreement. Contact our team to discuss how this model can be adapted to your specific therapeutic candidate.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver BIU-87 xenograft studies that meet the exacting standards of global pharmaceutical and biotechnology partners. Our differentiated value proposition includes:

• Proven model expertise with documented 92.9% orthotopic tumor take rate and validated subcutaneous engraftment protocols.
• Dual-route capability (subcutaneous and orthotopic) with integrated MRI monitoring for translational depth.
• GLP-aligned study conduct, IACUC-approved protocols, and AAALAC-accredited animal facilities.
• Customizable endpoints including histopathology, immunohistochemistry (Ki67, CD34, PSCA), apoptosis profiling, and PK/PD integration.
• Dedicated project management with weekly progress updates, real-time data access, and rapid timeline execution.
• Competitive pricing without compromising scientific quality or regulatory compliance standards.

Contact Us

Ready to advance your bladder cancer therapeutic program with a validated BIU-87 xenograft model? Contact us today to discuss your study objectives, timeline, and endpoint requirements. Reach out to our team of oncology model specialists for a customized proposal and feasibility assessment tailored to your preclinical needs. Please reach out to us today via our inquiry form or email to learn more about our BIU-87 Xenograft Model services.

For research use only. Not intended for any clinical use.